Literature DB >> 18928670

Human papillomavirus testing for primary cervical cancer screening.

Carolyn D Runowicz1, Stephanie Garozzo.   

Abstract

With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in screening for cervical cancer, and also analyzes the impact of the HPV vaccine on screening cytology.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18928670     DOI： 10.1007/s11912-008-0081-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  24 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

Review 2.  Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies.

Authors:  George Koliopoulos; Marc Arbyn; Pierre Martin-Hirsch; Maria Kyrgiou; Walter Prendiville; Evangelos Paraskevaidis
Journal:  Gynecol Oncol       Date:  2006-11-03       Impact factor: 5.482

Review 3.  American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors.

Authors:  Debbie Saslow; Philip E Castle; J Thomas Cox; Diane D Davey; Mark H Einstein; Daron G Ferris; Sue J Goldie; Diane M Harper; Walter Kinney; Anna-Barbara Moscicki; Kenneth L Noller; Cosette M Wheeler; Terri Ades; Kimberly S Andrews; Mary K Doroshenk; Kelly Green Kahn; Christy Schmidt; Omar Shafey; Robert A Smith; Edward E Partridge; Francisco Garcia
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

4.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

Review 5.  Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues.

Authors:  Robert A Smith; Vilma Cokkinides; Otis Webb Brawley
Journal:  CA Cancer J Clin       Date:  2008-04-28       Impact factor: 508.702

6.  Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3.

Authors:  Laura Kotaniemi-Talonen; Ahti Anttila; Nea Malila; Jussi Tarkkanen; Pekka Laurila; Matti Hakama; Pekka Nieminen
Journal:  Eur J Cancer       Date:  2008-01-08       Impact factor: 9.162

7.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

8.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

9.  HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial.

Authors:  H C Kitchener; M Almonte; P Wheeler; M Desai; C Gilham; A Bailey; A Sargent; J Peto
Journal:  Br J Cancer       Date:  2006-06-13       Impact factor: 7.640

10.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
View more
  1 in total

1.  Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation.

Authors:  P A Tarallo; J Smolowitz; D Carriero; J Tarallo; A Siegel; H Jia; J C Emond
Journal:  Transpl Infect Dis       Date:  2013-05-06       Impact factor: 2.228
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.